Browse the evidence

Long-term adherence to GLP-1 receptor agonist therapy significantly reduces the risk of major adverse liver outcomes (MALO) in patients with chronic liver disease and type 2 diabetes, whereas intention-to-treat analysis shows no significant benefit due to high discontinuation rates.

If you have chronic liver disease and type 2 diabetes, GLP-1 medications (like semaglutide or liraglutide) can significantly lower your risk of serious liver complications (like cirrhosis or liver cancer) over 10 years, BUT only if you keep taking them. Half of the patients in this study stopped taking the drug, which erased the benefit in the general group. To get the liver protection, you must manage side effects and stay on the treatment long-term.

Semaglutide is associated with a significantly higher reporting odds ratio for gastrointestinal adverse drug reactions (GADRs) compared to liraglutide, with a later median time-to-onset (7 days vs 4 days).

If you are considering GLP-1 weight loss drugs, know that semaglutide is associated with a higher reporting rate of stomach issues (nausea, vomiting, etc.) and a later onset of these symptoms compared to liraglutide. To minimize side effects, insist on a slow dose titration starting at the lowest dose. If semaglutide causes intolerable side effects, discuss switching to liraglutide, which may have a different gastrointestinal risk profile.

A single subcutaneous injection of a biomimetic hydrogel depot containing GLP-1 receptor agonists (semaglutide or liraglutide) sustains therapeutic drug exposure for approximately 42 days in rats, enabling a once-every-4-months dosing regimen in humans that maintains blood glucose and weight management comparable to daily or weekly injections.

This research suggests that a new type of injection using a hydrogel depot could allow people with type 2 diabetes to take their GLP-1 medication (like semaglutide or liraglutide) only once every four months instead of daily or weekly. In animal studies, this single shot kept blood sugar and weight under control just as well as taking the drug every day. While the technology is promising, it is currently only proven in rats, so human dosing and safety are not yet confirmed.

In lean individuals with low baseline triglycerides, carbohydrate-restricted diets cause elevated LDL-C and HDL-C through increased hepatic VLDL secretion and lipoprotein lipase (LPL)-mediated turnover, rather than through atherogenic dyslipidemia mechanisms.

If you are lean and keep your triglycerides low while eating low-carb, your LDL might rise significantly. This paper suggests this is likely due to efficient fat burning (high LPL activity) rather than the dangerous type of high cholesterol seen in obesity/diabetes. Monitor your triglycerides and HDL; if TG is low and HDL is high, the high LDL may be less concerning, though long-term cardiovascular outcomes in this specific group require more research.

GLP-1 receptor agonists (GLP-1RAs) activate brown adipose tissue (BAT) in humans, increasing its metabolic volume and glucose uptake, although this activation does not necessarily translate to increased fat fraction reduction or resting energy expenditure in all clinical contexts.

If you are using a GLP-1 medication like semaglutide or liraglutide, part of its benefit comes from activating your brown fat, which burns energy as heat. This happens alongside reduced appetite. While this doesn't always show up as 'less fat' in immediate scans, it contributes to better metabolic health and weight management. Stick with the treatment as prescribed.

A ketogenic diet reduces oxidative stress and improves mitochondrial function by activating antioxidant pathways (Nrf2) and scavenging reactive oxygen species (ROS) via ketone bodies like beta-hydroxybutyrate.

Adopting a ketogenic diet may help reduce cellular damage associated with aging and chronic disease by shifting your body's energy source to ketones, which appear to protect mitochondria and reduce oxidative stress.

Type 2 diabetes mellitus impairs weight reduction in obese patients primarily through energy conservation (reduced glucosuria), hyperinsulinemia-driven lipid storage, and the use of obesogenic anti-diabetes medications.

If you have Type 2 Diabetes and struggle to lose weight, it is likely not just a willpower issue. Your body is conserving energy because your blood sugar is better controlled (less sugar peed out), and medications like insulin or sulfonylureas may be actively promoting fat storage. Discuss switching to diabetes medications that support weight loss (such as GLP-1 agonists or SGLT2 inhibitors) with your doctor, as these can help overcome these physiological barriers.

Improvement in glycemic control in T2D patients leads to energy conservation via reduced glucosuria and osmotic water weight loss, which mechanically impedes scale-based weight reduction.

When you start treating your diabetes effectively, your blood sugar drops. This means your body stops peeing out calories (glucosuria) and starts storing water and glycogen again. You might see the scale go up by a few pounds. This is not fat gain; it is your body recovering from dehydration and energy loss. Do not stop your diabetes treatment because of this scale increase.

Obesogenic anti-diabetes medications, specifically those that increase insulin exposure (insulin, sulfonylureas, meglitinides), actively promote weight gain and hypoglycemia, which necessitates increased caloric intake and impairs weight loss.

If you are taking insulin, sulfonylureas, or meglitinides, these drugs may be making weight loss impossible by causing low blood sugar (hypoglycemia). To prevent lows, you may be eating extra carbs. Ask your doctor about switching to diabetes medications that do not cause hypoglycemia or weight gain, such as GLP-1 agonists or SGLT2 inhibitors.

High intake of saturated fat is not associated with increased risk of cardiovascular disease or mortality, and may be associated with lower total mortality and stroke risk in observational studies.

Observational data from large global cohorts suggests that saturated fat intake is not linked to higher heart disease or stroke risk, and may be linked to lower overall mortality. This challenges the standard advice to strictly limit these fats.

Semaglutide administration reduces visceral fat accumulation and improves glucose intolerance in obese mice by downregulating key lipogenic proteins (CD36, FABP5, ACSL, PLIN2) in epididymal white adipose tissue.

In this mouse study, semaglutide reduced fat mass by altering how fat cells store and process lipids, specifically by downregulating proteins like CD36 and PLIN2. This suggests that GLP-1 therapies may have direct peripheral effects on fat tissue metabolism, not just central appetite control. For humans, this supports the use of GLP-1 agonists for obesity management, though human dosing and response may vary.

Semaglutide therapy alters energy partitioning, resulting in a greater proportion of fat-free mass loss relative to fat loss compared to predictions based on standard energy density models.

Semaglutide may cause you to lose more muscle mass relative to fat than standard dieting. Ensure you are consuming adequate protein and engaging in resistance training to mitigate this specific side effect.

Artificial Intelligence (AI) and machine learning models can significantly improve the prediction of obesity prevalence and risk by analyzing complex interactions between behavioral, metabolic, and environmental data.

Be open to using wearable technology and health apps that use AI to predict your obesity risk. These tools can provide personalized insights into your lifestyle and metabolic health, helping you make better decisions.

Bupropion/naltrexone combination therapy has questionable cardiovascular safety and modest weight loss effects.

Bupropion/naltrexone is a combination medication that can lead to modest weight loss (4-5%). However, its cardiovascular safety is uncertain, and the trial was terminated early. It is not as effective or safe as newer GLP-1 agonists.

Semaglutide treatment (1 mg/week) in people with HIV and metabolic dysfunction-associated steatotic liver disease causes a significant decrease in psoas muscle volume (~9.3%) without causing a statistically significant decline in physical function (gait speed and chair rise tests).

If you are taking semaglutide for weight loss or liver health, expect to lose some muscle volume along with fat. This study suggests your physical function (like walking speed and ability to stand up) may not decline, but to be safe, incorporate resistance training into your routine to help preserve muscle mass and strength.

The effect of Tirzepatide on Fat-Free Mass (FFM) is inconclusive and uncertain, with evidence showing significant FFM loss that may be greater than or comparable to other anti-obesity drugs depending on the dose and study.

Current research does not provide a clear answer on whether Tirzepatide preserves muscle mass better than other weight loss strategies. Some studies indicate significant muscle loss occurs alongside fat loss, while others suggest it might be less severe than with other drugs. More research is needed to determine if specific dosing protects lean mass.

GLP-1 RAs show potential to slow the progression of neurodegenerative diseases, including Alzheimer's and Parkinson's, by reducing neuroinflammation and potentially acting as neuroprotective agents.

Research suggests GLP-1 medications may help protect against Alzheimer's and Parkinson's disease by reducing brain inflammation. While not yet a standard treatment for these conditions, ongoing clinical trials are investigating their use. If you have risk factors for cognitive decline, discussing these emerging benefits with your doctor may be relevant, especially if you are already using GLP-1s for diabetes or weight management.

Genetic predisposition to higher gut microbial butyrate production potential is causally linked to improved insulin response during an oral glucose tolerance test, while higher fecal propionate levels are causally linked to an increased risk of type 2 diabetes.

Your genetics influence how your gut bacteria process fiber into metabolites. While butyrate production is linked to better insulin response, high levels of propionate in stool have been causally linked to a higher risk of type 2 diabetes in genetic studies. This highlights the complexity of gut health beyond just 'eating fiber'.

GLP-1 receptor agonists may provide direct anti-inflammatory and disease-modifying benefits to osteoarthritic joints, independent of weight loss, by reducing pro-inflammatory cytokines and protecting chondrocytes.

Beyond helping you lose weight, GLP-1 medications might directly protect your knee joints from wear and tear. Research suggests these drugs can reduce inflammation within the joint itself and slow down cartilage loss, even independent of weight changes. This means you might experience less pain and slower progression of osteoarthritis, making these drugs a potentially dual-purpose treatment for both obesity and joint health.

Oral superabsorbent hydrogel (OSH) administration prevents diet-induced obesity and metabolic syndrome in mice by preserving gut barrier integrity and expanding Akkermansia muciniphila.

This research suggests that a specific type of hydrogel, when taken with meals, may help prevent weight gain and metabolic issues by protecting the gut lining and encouraging the growth of beneficial bacteria (A. muciniphila). While promising in mice, this is not yet a proven human therapy. Focus on proven methods like diet and exercise for now.

OSH administration improves metabolic parameters, including glucose tolerance and insulin sensitivity, by increasing GLP-1 levels and protecting the intestinal barrier.

This study indicates that OSH may help regulate blood sugar and insulin levels in mice by boosting GLP-1. This is a potential benefit for metabolic health, but more research is needed to see if it applies to humans.

OSH administration expands Akkermansia muciniphila abundance in the gut microbiota, which is associated with improved metabolic health.

This study shows that OSH can increase the levels of Akkermansia muciniphila, a bacterium linked to better metabolic health, in mice. This is a promising area of research, but it is not yet a proven strategy for humans.

Semaglutide use is associated with acute kidney injury (AKI), specifically acute interstitial nephritis (AIN) and podocytopathies (FSGS/MCD), particularly in patients with pre-existing chronic kidney disease (CKD) or advanced age.

If you are taking semaglutide and notice swelling, changes in urination, or fatigue, report it to your doctor immediately, especially if you have existing kidney disease. Most cases of kidney injury from semaglutide are reversible if the drug is stopped early and treated with steroids.

Long-acting GLP-1 receptor agonist (Ex-4)2-Fc promotes adipose tissue browning and thermogenesis in high-fat diet mice by enriching gut Lactobacillus reuteri and reducing serum ceramide levels via upregulation of alkaline ceramidase 2 (Acer2).

This research suggests that GLP-1 agonists do more than just suppress appetite; they actively change how fat tissue works by promoting 'browning' (heat production) and improving lipid metabolism. This effect is linked to changes in gut bacteria (specifically Lactobacillus reuteri) and the reduction of harmful lipids called ceramides. For individuals considering GLP-1 therapy, this highlights that the drug works through complex biological pathways beyond just eating less, potentially offering metabolic benefits even at lower doses when combined with healthy gut flora.